NCT04201210招募中2 期
A Phase II Stratified Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With Sickle Cell Disease With no Available Sibling Donor
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 212
- 试验地点
- 14
- 主要终点
- Primary efficacy endpoint: Composite Endpoint: Event free survival (EFS).
研究概览
简要总结
HSCT is currently the only curative option for SCD but less than 20% of SCD patients have a MD donor available. So far, all curative approaches beyond a MSD HSCT at young age are non-satisfactory. With the lack of a suitable donor for the vast majority of patients, the major question of this trial is, if a haploidentical αß/CD19+ T-cell depleted HSCT can be a valid alternative to a MSD HSCT. The main challenge in non-malignant diseases is to offer a safe and GvHD-free HSCT without rejection.
详细描述
Can an α/ß depleted T-Haplo-HSCT with regard to disease free survival, adverse events and safety be considered equivalent to a matched sibling donor transplantation (MSD), in order to offer cure for the majority of patients with sickle cell disease.
The main questions of this trial are:
- Safety of a α/ß T-depleted haploidentical HSCT
- Incidence of acute and chronic GvHD
- Rate of rejection
- Immune reconstitution
- Fertility It is expected that the use of TCRαβ+ and CD19+ depleted haploidentical cell grafts in combination with the less aggressive and well tolerated conditioning regimen needed for patient preparation will be associated with a low risk of grade II-IV aGVHD and no extensive cGvHD, no graft failure and increase speed, spectrum and functionality of immune system reconstitution. This is supposed to reduce the incidence of severe infections leading to lower rates of transplantation related mortality (TRM).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 35 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 2yrs to 35yrs
- •Homozygous hemoglobin S disease or heterozygous hemoglobin SC or S 0/+
- •Study specific consent given
- •Preexisting severe or moderate SCD related complications:
- •Clinically significant neurological event (stroke) or deficit
- •Silent crisis, neurocognitive deficit
- •Pathological angio-MRI with TOF Sequence
- •TCD velocity >200 cm/s at 2 occasions >1 month apart
- •More than 5 vaso-occlusive crises (VOC) in the past 1 year or more than 20 VOC in a lifetime
- •Two or more episodes of acute chest syndrome (ACS) in a lifetime or one episode of ACS in the past 24 months
- •Chronic transfusion requirement or more than 8 transfusions or one exchange transfusion in a lifetime
- •Transfusion-refractory allo-immunization
- •More than five SCD-related hospitalizations in a lifetime
- •Beginning pulmonary hypertension
- •Osteonecrosis at more than 2 sites
- •Beginning SCD Nephropathy
- •Recurrent priapism (>2)
排除标准
- •Karnofsky or Lansky Performance Score < 70%
- •Patients with donor-specific antibodies (DSA) against the potential stem cell donor by either
- •Cell-based crossmatched assays (Complement-dependent cytotoxicity; CDC) or
- •Flow cytometry crossmatch test or
- •Solid-phase immunoassays (SPI) or
- •Modified SPI such as C4d and C1q assays Whichever method the participating center is experienced in.
- •Patients with major AB0 incompatibility defined according to EBMT Handbook, Edition 2019 Tab 23.1.:
- •ABO incompatibility Recipient Donor Major O A O B O AB A AB B AB
- •Cardiac function:
- •Ejection fraction at rest <45.0% on echocardiography or
- •Shortening fraction of <27.0% by echocardiogram or radionuclide scan (MUGA)
- •Patients with > grade II hypertension by Common Toxicity Criteria (CTC)
- •Renal function:
- •Estimated creatinine clearance (for patients > 12 years) greater than 50.0 mL/minute
- •for pediatric patients (> 1 year to 12 years), GFR estimated by the updated Schwartz formula ≥ 90.0 mL/min/1.73 m
- •If < 90 mL/min/1.73 m2, renal function must be measured by 24-hour creatinine clearance or nuclear GFR and must be > 70.0 mL/min/1.73 m2 or
- •Creatinine clearance below threshold defined for stem cell transplantation according to local clinical standard
- •Pulmonary function:
- •DLCO >50% (adjusted for hemoglobin), and FVC and FEV1≥50%; children unable to perform for PFTs, O2 saturation <92% on room air.
- •Liver function:
- •Total bilirubin > 2x the upper limit of normal (unless elevated bilirubin is attributed to Gilbert's Syndrome) and ALT/AST > 2.5x the upper limit of normal.
- •Chronic active viral hepatitis
- •Women who are pregnant (positive serum or urine βHCG) or breastfeeding. Note: Women of childbearing potential must have a negative serum pregnancy test at study entry.
- •Adults of reproductive potential not willing to use an effective method of birth control during study treatment and for at least 12 months thereafter,
- •History of uncontrolled autoimmune disease or on active treatment
- •Patient unable to comply with the treatment protocol
- •Prior autologous or allogeneic hematopoietic stem cell transplant
- •Vaccination with a live virus vaccine during the trial
- •HIV infection
- •Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction)
- •Patients unwilling or unable to comply with the protocol or unable to give informed consent.
- •Concurrent severe or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months prior to the study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which by assessment of the treating physician could compromise participation in the study
结局指标
主要结局
Primary efficacy endpoint: Composite Endpoint: Event free survival (EFS).
时间窗: day 0 - day180
Event is defined as incidence of acute GvHD (Grade III - IV), chronic GvHD (moderate/severe), graft failure (GF), or death (from any reason).
次要结局
- Disease free survival(up to 2 years after transplantation)
- Quality of life: FACT-BMT(up to 2 years after transplantation)
- Graft failure(up to 2 years after transplantation)
- Overall survival(up to 2 years after transplantation)
- Quality of life: EQ-5D(up to 2 years after transplantation)
- Quality of life: PedsQL(up to 2 years after transplantation)
研究者
Prof. Dr. med. Selim Corbacioglu
Head of the department
University of Regensburg
研究点 (14)
Loading locations...
相似试验
Unknown
2 期
Concurrent Chemo-radiotherapy With Capecitabine for Unresectable Locally Advanced Pancreatic CarcinomaPancreatic CancerNCT00658840National Cancer Center, Korea55
Unknown
2 期
Utidelone in Third-line and Above Treatment of Small Cell Lung CancerSCLC, Extensive StageNCT05299255Henan Cancer Hospital40
Unknown
2 期
Safety and Efficacy Study of Target Therapy Combined With Radiotherapy to Treat Senile Locally Advanced SCCHNSCCHNNCT01393184Peking University92
已完成
2 期
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung CancerSmall Cell Lung CancerNCT00613626Hoosier Cancer Research Network74
已完成
2 期
CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying TherapyMultiple SclerosisNCT05131828Cambridge University Hospitals NHS Foundation Trust70